全文获取类型
收费全文 | 305822篇 |
免费 | 38964篇 |
国内免费 | 2879篇 |
专业分类
耳鼻咽喉 | 7568篇 |
儿科学 | 10228篇 |
妇产科学 | 5734篇 |
基础医学 | 24370篇 |
口腔科学 | 6687篇 |
临床医学 | 36486篇 |
内科学 | 83918篇 |
皮肤病学 | 11723篇 |
神经病学 | 27017篇 |
特种医学 | 10596篇 |
外国民族医学 | 4篇 |
外科学 | 61178篇 |
综合类 | 1127篇 |
现状与发展 | 72篇 |
一般理论 | 44篇 |
预防医学 | 22376篇 |
眼科学 | 6892篇 |
药学 | 11923篇 |
1篇 | |
中国医学 | 844篇 |
肿瘤学 | 18877篇 |
出版年
2023年 | 5648篇 |
2022年 | 1992篇 |
2021年 | 6287篇 |
2020年 | 7536篇 |
2019年 | 5544篇 |
2018年 | 12947篇 |
2017年 | 10635篇 |
2016年 | 11684篇 |
2015年 | 12148篇 |
2014年 | 19676篇 |
2013年 | 21935篇 |
2012年 | 16556篇 |
2011年 | 17248篇 |
2010年 | 16122篇 |
2009年 | 18381篇 |
2008年 | 14984篇 |
2007年 | 13869篇 |
2006年 | 15533篇 |
2005年 | 12805篇 |
2004年 | 11176篇 |
2003年 | 9691篇 |
2002年 | 9216篇 |
2001年 | 8380篇 |
2000年 | 8214篇 |
1999年 | 7177篇 |
1998年 | 4371篇 |
1997年 | 3966篇 |
1996年 | 3822篇 |
1995年 | 3590篇 |
1994年 | 2226篇 |
1993年 | 1832篇 |
1992年 | 2987篇 |
1991年 | 2799篇 |
1990年 | 2332篇 |
1989年 | 2265篇 |
1988年 | 1965篇 |
1987年 | 1769篇 |
1986年 | 1819篇 |
1985年 | 1557篇 |
1984年 | 1181篇 |
1983年 | 1037篇 |
1982年 | 781篇 |
1979年 | 889篇 |
1978年 | 695篇 |
1977年 | 725篇 |
1975年 | 703篇 |
1974年 | 729篇 |
1973年 | 769篇 |
1972年 | 793篇 |
1970年 | 698篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Martín-Nares Eduardo Zuñiga-Tamayo Diego Hinojosa-Azaola Andrea 《Clinical rheumatology》2019,38(1):97-106
Clinical Rheumatology - We aimed to estimate the frequency of overlap of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with systemic autoimmune diseases. Retrospective... 相似文献
92.
93.
M. Iachina P.M. Ljungdalh R.G. Sørensen L. Kaerlev J. Blaakær O. Trosko N. Qvist B.M. Nørgård 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):115-123
Aims
To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.Materials and methods
The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.Results
In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).Conclusions
We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis. 相似文献94.
Quang Ngoc Nguyen Linh Dieu Vuong Van-Long Truong To Van Ta Nam Trung Nguyen Hung Phi Nguyen Ha Hoang Chu 《Pathology, research and practice》2019,215(5):885-892
Genetic and epigenetic alterations importantly contribute to the pathogenesis of lung cancer. In the study, we measured the frequency and distribution of molecular abnormalities of EGFR as well as the aberrant promoter methylations of BRCA1, MGMT, MLH1, and RASSF1A in Vietnamese lung adenocarcinomas. We investigated the association between genetic and epigenetic alteration, and between each abnormality with clinicopathologic parameters. Somatic EGFR mutation that was found in 49/139 (35.3%) lung adenocarcinomas showed a significant association with young age, female gender, and non-smokers. EGFR overexpression was identified in 82 tumors (59.0%) and statistical relationships with EGFR or BRCA1 methylation but not EGFR mutation. In addition, EGFR, BRCA1, MGMT, MLH1, and RASSF1A methylations were found in 33 (23.7%), 41 (29.5%), 46 (33.1%), 28 (20.1%), and 41 (29.5%) cases of a total of 139 lung adenocarcinomas, respectively. The RASSF1A methylation was found to be linked to the smoking habit. Methylations in MGMT and RASSF1A were also found to correlate with metastasis status. Furthermore, the distribution of EGFR mutation and that of BRCA1, MGMT or RASSF1A methylation were significantly exclusive in lung adenocarcinomas. The main finding of our study demonstrate that epigenetic abnormalities might play a critical role for the lung tumorigenesis in patients with smoking history and metastasis, and partly affect the predictive value of EGFR mutations through blocking expression due to promoter EGFR hypermethylation. Mutually exclusive distribution of genetic and epigenetic alterations reflects differently biological characteristics in the etiology of lung adenocarcinomas. 相似文献
95.
96.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
97.
98.
Tormo Nuria Giménez Estela Martínez-Navarro María Albert Eliseo Navalpotro David Torres Ignacio Gimeno Concepción Navarro David 《European journal of clinical microbiology & infectious diseases》2022,41(4):657-662
European Journal of Clinical Microbiology & Infectious Diseases - We compared the performance of an in-house-developed flow cytometry assay for intracellular cytokine staining (FC-ICS) and a... 相似文献
99.
100.